anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To prepare a readily drinkable suspension formulation, soft and pleasant to the palate, having masked strong bitterness of a digestive agent and stable and good in uniformity even when preserved for a long period. SOLUTION: This suspension formulation comprises 0.01-0.05wt./vol.% digestive agent (e.g. ursodeoxycholic acid), 2-20wt./vol.% inorganic antacid (e.g. magnesium metasilicate aluminate), 0.01-5wt./vol.% xanthan gum and 0.1-20wt./vol.% modified starch (e.g. hydroxypropyl starch) as active ingredients. Furthermore, usual ingredients are suitably blended therewith and the resultant blend as converted into a uniform suspension by using a homogenizer, etc., according to a conventional method and, as necessary, sterilized by heating, etc., to afford the objective substance. The suspension formulation is capable of maintaining a stable suspended state even when preserved for a long period and the redispersion thereof can readily by carried out in a short time even in the case of performing the sedimenting and separating.  Furthermore, the suspension formulation is effective in promoting digestion and reducing symptoms such as gastric and abdominal inflations, gastralgia or gastric hyperacidity caused by dyspepsia, anorexia, excessive eating, a dull feeling in the stomach or lying of foods heavy in the stomach.
A pharmaceutical composition includes an effective amount of a peptide or an analog thereof, and a pharmaceutically tolerable excipient, wherein the peptide includes the amino acid sequence of SEQ ID NO. 17. An analog of a peptide including the amino acid sequence of SEQ ID NO. 17, wherein one or more amino acids residues are modified by a) C-terminal modification; b) D-amino acid substitution; and/or c) deletion of one or more amino acid residues. A method of inhibiting the growth of a microorganism includes contacting the microorganism in a medium with an effective amount of a peptide or an analog thereof, wherein the peptide includes the amino acid sequence of SEQ ID NO. 17. A method of treating a disease or disorder associated with microbial activity in a subject includes administering an effective amount of a peptide or an analog thereof to the subject, the peptide including the amino acid sequence of SEQ ID NO. 17.
<P>PROBLEM TO BE SOLVED: To provide an oxidation dyeing composition for keratin fibers, in particular human keratin fibers and more particularly hairs.  <P>SOLUTION: This invention relates to an oxidation dyeing composition for keratin fibers, particularly human keratin fibers and more particularly hairs. The composition includes at least one oxidation dye, at least one 10-14C fatty alcohol and a cationic poly(vinyllactam). In the composition, easiness in mixing of an oxidizing agent with other optional ingredients is increased, a foaming characteristic is improved, easiness in removal during rinsing is particularly improved and thus, the composition can be applied instantaneously. The dyeing method and device using the composition are also provided.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Risk Summary

Discontinue NEXLETOL when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.

There are insufficient data on NEXLETOL use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, bempedoic acid was not teratogenic in rats and rabbits when administered at doses resulting in exposures up to 11 and 12 times, respectively, the human exposures at the maximum clinical dose, based on AUC (see Data). NEXLETOL decreases cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol; therefore, NEXLETOL may cause fetal harm when administered to pregnant women based on the mechanism of action [see Clinical Pharmacology (12.1)]. In addition, treatment of hyperlipidemia is not generally necessary during pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperlipidemia for most patients.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Report pregnancies to the Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633.

Data

Animal Data

Bempedoic acid was not teratogenic when given orally at doses of 60 and 80 mg/kg/day, resulting in 11 and 12 times the systemic exposure in humans at the maximum recommended human dose (MRHD) of 180 mg to pregnant rats and rabbits, respectively. In an embryofetal development study in rats, bempedoic acid was given orally to pregnant rats at 10, 30, and 60 mg/kg/day during the period of organogenesis from gestation day 6 to 17. There were increases in the incidence of non-adverse fetal skeletal variations (bent long bones and bent scapula and incomplete ossification) at doses ≥ 10 mg/kg/day (less than the clinical exposure) in the absence of maternal toxicity. At maternally toxic doses, bempedoic acid caused decreases in the numbers of viable fetuses, increases in post-implantation loss, and increased total resorptions at 60 mg/kg/day (11 times MRHD) and reduced fetal body weight at ≥ 30 mg/kg/day (4 times the MRHD). No adverse development effects were observed when bempedoic acid was given to pregnant rabbits during the period of organogenesis (gestation day 6 to 18) at doses up to 80 mg/kg/day (12 times MRHD).

In a pre- and post-natal development study in pregnant rats given oral doses of bempedoic acid at 5, 10, 20, 30 and 60 mg/kg/day throughout pregnancy and lactation (gestation day 6 to lactation day 20), there were adverse effects on delivery in the presence of maternal toxicity, including: increases in stillborn pups, reductions in numbers of live pups, pup survival, pup growth and slight delays in learning and memory at ≥ 10 mg/kg/day (at exposures equivalent to the MRHD).
BACKGROUND: Stress-induced Exhaustion Disorder (ED) is associated with work absenteeism and adverse health outcomes. Currently, little is known regarding how the symptoms of ED are interrelated and whether the patterns of symptoms influence treatment outcomes. To this end, the current study applied network analyses on ED patients participating in a multimodal intervention.
METHODS: The first aim of the study was to explore the internal relationships between exhaustion symptoms and identify symptoms that were more closely related than others. A second aim was to examine whether the baseline symptom network of non-responders to treatment was more closely connected than the baseline symptom networks of responders, by comparing the sum of all absolute partial correlations in the respective groups' symptom network. This comparison was made based on the hypothesis that a more closely connected symptom network before treatment could indicate poorer treatment outcomes. Network models were constructed based on self-rated ED symptoms in a large sample of patients (n = 915) participating in a 24-week multimodal treatment program with a 12-month follow-up.
RESULTS: The internal relations between self-rated exhaustion symptoms were stable over time despite markedly decreased symptom levels throughout participation in treatment. Symptoms of limited mental stamina and negative emotional reactions to demands were consistently found to be the most closely related to other ED symptoms. Meanwhile, sleep quality and irritability were weakly related to other exhaustion symptoms. The symptom network for the full sample became significantly more closely connected from baseline to the end of treatment and 12-month follow-up. The symptom network of non-responders to treatment was not found to be more closely connected than the symptom network of responders at baseline.
CONCLUSIONS: The results of the current study suggest symptoms of limited mental stamina and negative emotional reactions to demands are central ED symptoms throughout treatment, while symptoms of irritability and sleep quality seem to have a weak relation to other symptoms of ED. The implications of these findings are discussed in relation to the conceptualization, assessment, and treatment of ED.
TRIAL REGISTRATION: The clinical trial was registered on Clinicaltrials.gov 2017-12-02 (Identifier: NCT03360136).
A double-blinded prospective, randomized study undertaken at outpatient clinic of King Chulalongkorn Memorial Hospital. The patients with vitamin D insufficiency were included and divided into three groups according to their initial 25OHD concentrations. Patients are randomly assigned to receive vitamin D2 40000, 60000 or 80000 IU once weekly. Serum 25(OH)D levels are measured at 12 weeks after vitamin D2 supplemetaiton. The patients with 25OHD more than 30ng/mL are enroll into the maintenance phase of the study and are randomly assigned to receive vitamin D2 20000 or 40000 IU once weekly for another 12 months. The 25OHD concentration are measure again at the end of the study.
GSK3732394 600 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The administered dose in Part 2, Cohort 3 will be based on PK/PD results from preceding dosing cohorts and will not exceed the maximum exposure observed in SAD (Part 1).
PURPOSE:To provide the medical image preservation and communication system for easily setting and changing the distribution destination of image data corresponding to changes in the operating conditions of the system. CONSTITUTION:A medical image preservation and communication system 1 is connected through networks 3a and 3b to modalities 2a and 2b. This system 1 is provided with plural FS 4a and 4b for image data preservation, plural reading WS 5a-5c for displaying image data, automatic distribution controller 6 for controlling the distribution of image data or the like, and terminal 7 for control to perform the indication for distribution control. Then, the respective devices inside the system 1 are connected through a network 8. Among these devices, the automatic distribution controller 6 is functionally provided with an image managing information reception part 14, inspection request information reception part 15, distribution control part 16 and distribution setting control part 17 for registering a distribution destination table 18. Further, an RIS 9 outside the system 1 is connected to the network 8 as well.
PURPOSE:To inexpensively obtain the subject extract containing crude saponins in large amounts using a simple method by culturing and proliferating a tissue containing adventitious embryo obtained from vlable tissue of Panax ginseng C.A. Meyer and then extracting the ginseng extract from the proliferated tissue. CONSTITUTION:A tissue containing adventitious embryo is obtained from niable tissue of Panax ginseng C.A. Meyer, preferably by mass production, etc., of the adventitious embryo by culturing there of in a medium in which carbon source is adjusted to 40-200g/l. Then, the tissue containing the adventitious embryo is subjected to shaking culture using an air lift type fermenter to culture and proliferate the tissue and the objective extract is extracted from the proliferated tissue. Furthermore, number of adventitious embryo is preferably >=50/g of the tissue. The extraction of the objective extract is carried out e.g. by heating and extracting dried material of the adventitious embryo with methanol.
Esomeprazole magnesium is supplied as delayed-release capsules for oral administration. The recommended dosages are outlined in Table 1. Esomeprazole magnesium delayed-release capsules should be taken at least one hour before meals.

The duration of proton pump inhibitor administration should be based on available safety and efficacy data specific to the defined indication and dosing frequency, as described in the prescribing information, and individual patient medical needs. Proton pump inhibitor treatment should only be initiated and continued if the benefits outweigh the risks of treatment.

Please refer to amoxicillin and clarithromycin prescribing information for Contraindications, Warnings, and dosing in elderly and renally-impaired patients.

Specific Populations

Hepatic Insufficiency

In patients with mild to moderate liver impairment (Child‑Pugh Classes A and B), no dosage adjustment is necessary. For patients with severe liver impairment (Child‑Pugh Class C), a dose of 20 mg of esomeprazole magnesium delayed-release capsules should not be exceeded [see Clinical Pharmacology (12.3)] . 

Directions for use specific to the route and available methods of administration for each of these dosage forms are presented in Table 2.

Esomeprazole Magnesium Delayed-Release Capsules

Esomeprazole magnesium delayed-release capsules should be swallowed whole.

Alternatively, for patients who have difficulty swallowing capsules, one tablespoon of applesauce can be added to an empty bowl and the esomeprazole magnesium delayed-release capsule can be opened, and the granules inside the capsule carefully emptied onto the applesauce. The granules should be mixed with the applesauce and then swallowed immediately: do not store for future use. The applesauce used should not be hot and should be soft enough to be swallowed without chewing. The granules should not be chewed or crushed. If the granules/applesauce mixture is not used in its entirety, the remaining mixture should be discarded immediately.

For patients who have a nasogastric tube in place, esomeprazole magnesium delayed-release capsules can be opened and the intact granules emptied into a 60 mL catheter tipped syringe and mixed with 50 mL of water. It is important to only use a catheter tipped syringe when administering esomeprazole magnesium delayed-release capsules through a nasogastric tube. Replace the plunger and shake the syringe vigorously for 15 seconds. Hold the syringe with the tip up and check for granules remaining in the tip. Attach the syringe to a nasogastric tube and deliver the contents of the syringe through the nasogastric tube into the stomach. After administering the granules, the nasogastric tube should be flushed with additional water. Do not administer the granules if they have dissolved or disintegrated.

The mixture must be used immediately after preparation.
In PACT, parents are guided, generally in face to face, by a professional to improve the synchrony and communication with their children with ASD. Then, it is recommended to the parents to practice the therapy daily at home. In France, this type of early intervention is poorly developed and is only accessible in specialized centers located in large urban centers. Guiding parents by videoconferencing could make this intervention accessible to families in undeserved areas. The objective of this study is to evaluate the effectiveness of a PACT intervention delivered by parents and guided by videoconferencing, on the autism in their children with ASD, aged 18 to 36 months at the inclusion.

This study is a multicenter (5 centers), two-parallel-group, randomised controlled trial. It will compare a group of children receiving the usual therapy (TAU) and a group receiving TAU plus the PACT intervention. The primary outcome is the autism symptoms measured with the ADOS-2 (Autism Diagnostic Observation Schedule) at 12 months. A total of 238 children will be included in the study (119 per group).
The liver is the chief site of biotransformation of phenytoin; patients with impaired liver function, elderly patients, or those who are gravely ill may show early signs of toxicity. A small percentage of individuals who have been treated with phenytoin have been shown to metabolize the drug slowly. Slow metabolism may be due to limited enzyme availability and lack of induction; it appears to be genetically determined. If early signs of dose-related CNS toxicity develop, plasma levels should be checked immediately.

Hyperglycemia, resulting from the drug's inhibitory effects on insulin release, has been reported. Phenytoin may also raise the serum glucose level in diabetic patients.

Phenytoin is not indicated for seizures due to hypoglycemic or other metabolic causes. Appropriate diagnostic procedures should be performed as indicated.

Phenytoin is not effective for absence (petit mal) seizures. If tonic-clonic (grand mal) and absence (petit mal) seizures are present, combined drug therapy is needed.

Serum levels of phenytoin sustained above the optimal range may produce confusional states referred to as "delirium," "psychosis," or "encephalopathy," or rarely irreversible cerebellar dysfunction. Accordingly, at the first sign of acute toxicity, plasma levels are recommended. Dose reduction of phenytoin therapy is indicated if plasma levels are excessive; if symptoms persist, termination is recommended. (See section.) WARNINGS
A single or multiple overdose with hydrocodone and acetaminophen is a potentially lethal polydrug overdose, and consultation with a regional poison control center is recommended.

Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption. Vomiting should be induced mechanically, or with syrup of ipecac, if the patient is alert (adequate pharyngeal and laryngeal reflexes). Oral activated charcoal (1 g/kg) should follow gastric emptying. The first dose should be accompanied by an appropriate cathartic. If repeated doses are used, the cathartic might be included with alternate doses as required. Hypotension is usually hypovolemic and should respond to fluids. Vasopressors and other supportive measures should be employed as indicated. A cuffed endotracheal tube should be inserted before gastric lavage of the unconscious patient and, when necessary, to provide assisted respiration.

Meticulous attention should be given to maintaining adequate pulmonary ventilation. In severe cases of intoxication, peritoneal dialysis, or preferably hemodialysis may be considered. If hypoprothrombinemia occurs due to acetaminophen overdose, vitamin K should be administered intravenously.

Naloxone, a narcotic antagonist, can reverse respiratory depression and coma associated with opioid overdose. Naloxone hydrochloride 0.4 mg to 2 mg is given parenterally. Since the duration of action of hydrocodone may exceed that of the naloxone, the patient should be kept under continuous surveillance and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. A narcotic antagonist should not be administered in the absence of clinically significant respiratory or cardiovascular depression.

If the dose of acetaminophen may have exceeded 140 mg/kg, acetylcysteine should be administered as early as possible. Serum acetaminophen levels should be obtained, since levels four or more hours following ingestion help predict acetaminophen toxicity. Do not await acetaminophen assay results before initiating treatment. Hepatic enzymes should be obtained initially, and repeated at 24-hour intervals.

Methemoglobinemia over 30% should be treated with methylene blue by slow intravenous administration.

The toxic dose for acetaminophen for adults is 10 g.
PURPOSE:To quickly attain a diagnosis by a doctor under consideration of past information by linking medical data with picture data such as eye picture, preserving those data as electronic data, and displaying the data on a visual screen as necessary. CONSTITUTION:The picture obtained by photographing a patient is linked with picture data 26 and 35 corresponding to the patient, and registered. And also, when the name of a disease is inputted from a screen, the name of the desease is linked with medial data 12 and 34 corresponding to the patient, and registered. Then, the name of the patient and the name of the disease corresponding to a chart are taken out from the medical data 12 and 34, and displayed, and the picture of the patient is taken out from the picture data 26 and 35, and displayed. Then, the diagnostic result obtained by looking at those data is registered as the medial data 12 and 34 corresponding to the input of the diagnostic result. The means of the patient and an insurance number are temporarily preserved corresponding to the patient number as the medical data 12, and the preserved data are transmitted to a server machine 3, and managed in a batch as the medial data 34.
The interventional group will use the digital self-management smartphone application during the 12-week study period and will have access to 3 coaching sessions. The interventional group will be trained in the use of the app and receive education focused on self-monitoring blood glucose based on paired (before and 2 hours after a meal) blood glucose testing, which participants will conduct twice daily for 6 days once monthly for 3 months.
This trial is a multicenter real-world retrospective comparative study. The patients with thoracic esophageal squamous cell carcinoma, esophagectomy and adjuvant chemotherapy(Cisplatin plus Docetaxel or Lobaplatin plus Docetaxel) from 6 centers in China were enrolled from Jan.2013 to Dec.2016. Completed clinical and pathological data were collected from Large-scale Data Analysis Center of Cancer Precision Medicine-LinkDoc database and analyzed by using data technology support from LinkDoc by using R-language. A hybrid solution for extracting structured medical infromation from unstructured data in medical records via a double-reading/entry system. The World Health Organization (Toxicity Grading Scale for Determining the Severity of Adverse Events) was used. The side effects of adjuvant chemotherapy and overall survival rate were compared by a propensity score. The 6 centers are The affiliated Cancer Hospital of ZhengZhou university/Henan Cancer Hospital, Anyang Cancer Hospital, Anhui Province Hospital, The first affiliated Hospital of Anhui university, Tangdu Hospital/the affiliated Hospital of Fourth Military Medical University, The First Affiliated Hospital of Xi'an Jiao Tong University.
The invention discloses a medicinal liquor for treating hyperostosis. Because hyperostosis is usually caused by invasion of stasis and evil qi and unresolved stasis, the medicinal liquor is prepared on the basis of a traditional Chinese medicine theory of resolving stasis, dispelling evil qi, relaxing sinews, and activating collaterals and long-term clinical practice. The medicinal liquor is prepared by soaking the following traditional Chinese herbals by weight into 3000 mL of liquor (22 to 30 degree) for 10 days through a cold-soaking method: 60 grams of wild bighead atractylodes rhizome, 60 grams of Paris polyphylla, 60 grams of cassia twig, 60 grams of chrysanthemum, 60 grams of licorice, 80 grams of Chinese angelica, 50 grams of safflower, and 50 grams of dry prepared fleece-flower root. Patients can drink the medicinal liquor for 2 to 3 times a day according to the disease state and patients' physique, 20 to 25 milliliters for each time, at the same time the medicinal liquor should be smeared on the hyperostosis part, and one treatment course lasts for 10 days. The medicinal liquor has been applied to clinical application, and the curative effect is very good. After one to three treatment courses, the hyperostosis tissues are softened and eliminated, and most patients are cured and do not have any relapse.
Pyronaridine artesunate 6:2 mg/kg. The tablet strength is 48:16 mg oral PA, with the number of tablets depending on body weight.
Based on the WHO malaria treatment guidelines, a standard PQ regimen of 0.25 mg PQ base/kg body weight daily for 14 days was administered to eligible individuals through directly observed treatment (DOT) to ensure drug intake and monitor potential adverse effects during August-September 2019. The safety of each participant was monitored by follow-up blood testing using Hemocue's hemoglobin photometers to track changes in hemoglobin levels.